Refine
Document Type
- Article (3) (remove)
Has Fulltext
- yes (3)
Is part of the Bibliography
- no (3)
Keywords
- Abenteurer <Motiv> (1)
- Artemether-lumefantrine (1)
- Artemisinin-combination-therapy (1)
- Europa (1)
- Geschichte 1492-1920 (1)
- Held (1)
- Kongressbericht (1)
- Literatur (1)
- Malaria (1)
- Malariae (1)
- Mechanisms of disease (1)
- Molecular medicine (1)
- Non-falciparum (1)
- Ovale (1)
Institute
- Medizin (2)
- Geowissenschaften (1)
Waren die ersten Europäer Abenteurer? : Abenteurer als Helden der Literatur vom 16.-20. Jahrhundert
(2001)
Interdisziplinäre Euro-Konferenz der Universität GH Essen im Wissenschaftszentrum Bonn, 16.-19. Februar 2000 (Kongreßbericht)
Wenn der "Abenteurer" spätestens im 19. Jahrhundert zum Mythos aufgestiegen ist, so hat er es dennoch bis heute weder zu einem Artikel in einem der großen europäischen Konversationslexika gebracht - noch widmete ihm die historische Forschung (die ihn als eine Verfallserscheinung des Ancien régime beschrieb) je mehr als ein beiläufiges Interesse. Dabei ist der Abenteurer keineswegs allein ein Phänomen des 18. Jahrhunderts. Vielmehr kann man seine Gestalt vom 16. bis ins 20. Jahrhundert hinein verfolgen. Diese Kontinuität der abenteuerlichen Existenz seit dem 16. Jahrhundert bildete nun das Thema einer internationalen Forschungskonferenz, die die Universität GH Essen mit Unterstützung der Deutschen Forschungsgemeinschaft und der Europäischen Kommission veranstaltete.
Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. Resulting fibrosis and portal hypertension, as a possible secondary event, may necessitate treatment. Overexpression of mouse renin in the transgenic rat model, TGR(mREN2)27, leads to spontaneous development of NAFLD. Therefore, we used TGR(mREN2)27 rats as a model of NAFLD where we hypothesized increased susceptibility and investigated fibrosis and portal hypertension and associated pathways. 12-week old TGR(mREN2)27 rats received either cholestatic (BDL) or toxic injury (CCl4 inhalation). Portal and systemic hemodynamic assessments were performed using microsphere technique with and without injection of the Janus-Kinase 2 (JAK2) inhibitor AG490 or the non-peptidic Ang(1-7) agonist, AVE0991. The extent of liver fibrosis was assessed in TGR(mREN2)27 and wild-type rats using standard techniques. Protein and mRNA levels of profibrotic, renin-angiotensin system components were assessed in liver and primary hepatic stellate cells (HSC) and hepatocytes. TGR(mREN2)27 rats developed spontaneous, but mild fibrosis and portal hypertension due to the activation of the JAK2/Arhgef1/ROCK pathway. AG490 decreased migration of HSC and portal pressure in isolated liver perfusions and in vivo. Fibrosis or portal hypertension after cholestatic (BDL) or toxic injury (CCl4) was not aggravated in TGR(mREN2)27 rats, probably due to decreased mouse renin expression in hepatocytes. Interestingly, portal hypertension was even blunted in TGR(mREN2)27 rats (with or without additional injury) by AVE0991. TGR(mREN2)27 rats are a suitable model of spontaneous liver fibrosis and portal hypertension but not with increased susceptibility to liver damage. After additional injury, the animals can be used to evaluate novel therapeutic strategies targeting Mas.
Background: The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.
Methods: This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon.
Results: Forty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study.
Conclusions: This first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon.
Trial Registration: ClinicalTrials.gov Identifier: NCT00725777